Categories Health Care, IPO, Others
OptMed all set for $24 million IPO. Here’s what you need to know
As IPO activity picks up momentum after a lull, technology and healthcare companies are dominating the scene as usual. The upcoming initial public offering of medical device maker OptMed Inc. is one of the closely followed events of the year.
OptMed is planning to raise about $24 million through an initial public offering, as per a regulatory submission made by the company. It has applied to list the stock on the Nasdaq Capital Market under the symbol OMED. However, the management is yet to reveal the number of shares being offered and the offer price.
Read management/analysts’ comments on quarterly reports
EF Hutton is the underwriter for the offering. The company intends to use the net proceeds from the offering for product development, marketing activities, and repayment of debt. A part of the amount will be used for general corporate and working capital purposes.
OptMed, a clinical-stage medical device company, is mainly engaged in the development of topical skin protectant products and surgical adhesives, with a focus on the treatment of patients with external and internal wounds. BondEase, one of the lead products, got FDA approval a few years ago. Since then, the company has upgraded the product constantly. Due to the changes, it is required to submit a new clearance application with regulators, which is expected to be done a few weeks after the IPO.
Everything you need to know about Ivanhoe Electric’s upcoming IPO
Besides BondEase, OptiMed is also developing TearRepair Liquid Skin Protectant, which is a topical protectant for fragile skin.
Founded in 2007, OptMed is headquartered in New York and is headed by chief executive officer Dr. Ervin Braun. Being part of a rapidly emerging segment of the healthcare industry, OptMed should be able to strengthen its foothold in the market. It is estimated that the global market for surgical sealants and adhesives would reach $2.8 billion by 2025. However, the company will have to compete with established players who enjoy an edge due to their stronger resources and better experience.
In fiscal 2021, OptMed incurred a net loss of $4.38 million, compared to a loss of $3.38 million in the prior year. The bottom line was negatively impacted by a 13% increase in operating expenses to $2.84 million. The company is yet to generate revenues because it has not commercially launched any product so far. To a large extent, Its growth prospects would depend on obtaining regulatory approval for the lead products.
Looking for more insights on the earnings results? Click here to access the full transcripts of the latest earnings conference calls!
Key takeaways from General Mills’ Q3 2023 earnings report
Shares of General Mills Inc. (NYSE: GIS) were up nearly 3% on Thursday after the company delivered better-than-expected results for the third quarter of 2023 and raised its full-year guidance
FIVE Stock: Five Below is likely to continue the good show this year
For Five Below Inc. (NASDAQ: FIVE), the holiday season was more rewarding than expected as the high inflation and stressed personal finances made customers seek value. Earlier, the discount store
Earnings: Chewy (CHWY) swings to profit in Q4 on higher revenues
Chewy Inc. (NYSE: CHWY) has reported higher sales for the fourth quarter of 2022. Reflecting the strong top-line growth, the pet food company turned to profit from a loss last